ACTA ENDOCRINOLOGICA (BUC)

The International Journal of Romanian Society of Endocrinology / Registered in 1938

in Web of Science Master Journal List

Acta Endocrinologica(Bucharest) is live in PubMed Central

Journal Impact Factor - click here.

Year Volume Issue First page
10.4183/aeb.
Author
Title
Abstract/Title
From through

  • Endocrine Care

    Yalin GY, Uzum A, Selcukbiricik O, Yegen G, Gul N, Barbaros U, Yarman S

    Management of Silent Cystic Pheochromocytomas with Benign or Malignant Histology

    Acta Endo (Buc) 2015 11(2): 195-201 doi: 10.4183/aeb.2015.195

    Abstract
    abdominal cystic lesions should include investigation of cystic pheochromocytomas. To date only a few cases of purely cystic pheochromocytoma have been reported in the English literature. Aim. To present the management in four cases of silent pheochromocytomas patients who presented with pure or partially cystic abdominal lesions with benign (n:3) and malignant characteristics (nonspecific neuroendocrine tumor) (n:1) in histological evaluation. Results. Resection of the tumor is considered the primary treatment option in the management of pheochromocytoma, and preoperative preparation with alpha and beta antagonists is crucial in order to avoid precipitation of hypertensive crisis during surgical procedures. The absence of clinical symptoms and lack of typical radiological features may complicate the diagnosis of pheochromocytoma resulting with increased mortality and morbidity during surgery. Conclusion. Asymptomatic pheochromocytomas are rare and they are responsible for approximately 5% of adrenal incidentalomas. These lesions may be referred to surgery as clinically nonfunctional adrenal adenomas.
  • Endocrine Care

    Gokbulut P, Koc G, Kuskonmaz SM, Onder CE, Omma T, Firat S, Culha C

    High Thyroperoxidase Antibody Titers May Predict Response to Antithyroid Drug Treatment in Graves Disease: a Preliminary Study

    Acta Endo (Buc) 2023 19(2): 195-200 doi: 10.4183/aeb.2023.195

    Abstract
    Background and aim. Antithyroid drugs are first treatment for Graves hyperthyroidism worldwide. Although remission can be achieved in approximately 40-50% of patients in 12-18 months with antithyroid drugs, this period can be extended up to 24 months. We aimed to evaluate the effect of individual clinical/biochemical variables and GREAT score in predicting response to antithyroid drug in Graves disease. Material and methods. This is a retrospective single-center study including 99 patients with the first episode of Graves disease treated for at least 18 months. The patients were classified into two groups as those who responded to antithyroid medication at 18-24 months (group 1) and those who did not respond at 24 months and continued with low-dose antithyroid medication (group 2). Results. Medical treatment response was obtained in 38 (38.3%) of the patients at 18 months, and in 19 (19.1%) patients at 24 months. Long-term medical treatment (>24 months) was given to the remaining 43 patients due to the lack of response to medical treatment. Thyroid volume and free T4 levels were higher in those followed up with longterm antithyroid drugs, and orbitopathy was more common in this group. Median anti TPO value was significantly higher in group 1 when compared to group 2 (593 U/l and 191.6 U/l respectively). More patients were classified as GREAT class 3 in group 2 when compared to group 1 (46.5% and 12,5% respectively). We analyzed the Thyroperoxidase Antibody(anti TPO) titers, which we divided into three levels, according to groups 1 and 2. Post-hoc Chi-Square analysis revealed that falling into the highest anti TPO category was significantly associated with response to medical therapy in 24 months (p <0.05). Conclusion. According to our study, GREAT score and anti TPO Ab titers at presentation may help predict response to ATD in Graves disease
  • Endocrine Care

    Batman A, Altuntas Y

    Risk of Hypercalcemia in Elderly Patients with Hypervitaminosis D and Intoxication

    Acta Endo (Buc) 2021 17(2): 200-206 doi: 10.4183/aeb.2021.200

    Abstract
    Objective. We aimed to determine the risk of hypercalcemia in a geriatric population with very high dose levels of 25-hydroxy-vitamin D (25(OH)D). Patients and Method. This study was designed as a retrospective, cross-sectional two-center study for examining the elderly patients with very high 25(OH)D levels (>88ng/mL) between January 2014 and December 2019. After recruitment, subgroup analyses of the patients were performed based on their calcium and vitamin D levels. Results. A total of 81.101 elderly patients, who had been evaluated for their vitamin D levels, were screened. Of the 458 (0.6%) elderly patients with 25(OH)D>88 ng/ mL according to our criteria, 217 patients with complete data were accepted into our study. The median 25(OH)D level was 103.7ng/mL (min-max:88.2-275.9). Most of the elderly patients (86.6%) with very high 25(OH)D levels were normocalcemic. When patients with hypercalcemia were compared with normocalcemic group, no difference was observed in the levels of 25(OH)D, intact parathormone (iPTH), phosphorus, alkaline phosphatase (ALP), and their age. However, the PTH suppression rate was significantly higher in hypercalcemic group (p=0.005). Conclusion. The elderly patients with very high 25(OH)D levels would appear to be mostly normocalcemic whereas life-threatening hypercalcemia would also occur. Treatment and follow-up planning should be done according to the clinical guideline recommendations.
  • General Endocrinology

    Katergari SA, Milousis A., Passadaki T., Mantatzis M., Tripsianis G., Asimakopoulos B., Nikolettos N., Papachristou DN

    Postprandial Free Fatty Acids Are Related to Total Visceral and Retroperitoneal Fat in Dibetic Men

    Acta Endo (Buc) 2013 9(2): 201-218 doi: 10.4183/aeb.2013.201

    Abstract
    Objective. To evaluate circulating FFAs in relation to glucose and insulin metabolism and to different fat compartments in men with and without diabetes. Patients and Methods. Thirtythree men with uncomplicated type 2 diabetes mellitus (T2DM) and 28 controls underwent an oral fat load and were studied at baseline and for 5 hours postprandially for serum FFAs, glucose and insulin. Abdominal fat distribution and gluteal fat accumulation were evaluated by anthropometrics and axial MRI images. Insulin resistance and sensitivity were estimated by HOMA and Matsuda index respectively. Results. Fasting and postprandial FFAs were higher in diabetics (p=0.007) despite similar fat accumulation and distribution between groups. Postprandial FFAs correlated positively with postprandial glucose, and fasting and postprandial insulin levels (p< 0.05) in controls, and with fasting and postprandial insulin levels (p< 0.05 and p < 0.01 respectively) in diabetics. Postprandial FFAs were positively correlated to HOMA (p<0.01) and negatively to Matsuda index (p<0.05), and positively to total visceral and retroperitoneal fat,the strongest association observed at L2- L3 (p<0.05 and p<0.001 respectively) in diabetics. Conclusions. Diabetics have higher serum FFAs, despite similar levels of adiposity and fat distribution. Interestingly, postprandial FFAs correlate strongly and positively with total visceral fat, underlying the importance of visceral fat in metabolic abnormalities in diabetes.
  • Endocrine Care

    Fica SV, Albu A, Vadareanu F, Barbu C, Bunghez R, Nitu L, Marinescu D

    Endocrine disorders in ?-thalassemia major: cross-sectional data

    Acta Endo (Buc) 2005 1(2): 201-212 doi: 10.4183/aeb.2005.201

    Abstract References
    Chronic transfusion regimen and chelating therapy has dramatically improved the life expectancy of thalassemic patients. The aim of this study was to assess the prevalence of endocrine disturbances in patients with beta-thalassemia major. Subjects were 64 patients with a mean age of 19.45 ? 6.82 years found in haematological care at the National Institute of Transfusional Haematology. All the patients were evaluated clinically and biologically. LH, FSH, estradiol, testosterone, TSH, free T4, insulin were measured by chemiluminescence; mean ferritin value was used to assess iron overload. Fifty one patients (79.68%) -27 male and 24 female in our group were at pubertal or adult age. Eleven boys (40.74%) had delayed puberty, 10 (37%) arrested puberty and 4 (14.8%) had reached complete sexual maturation. In the female group, 6 (25%) had delayed puberty, 4 (16.66%) arrested puberty and 14 (58.32%) reached full sexual development. Half of both the male and female patients with complete sexual maturation had hypogonadotropic hypogonadism at the evaluation moment. Moreover, 34 (53.12%) of our patients had pathological short stature, 11 (17.18%) primary hypothyroidism, 5 (7.8%) hypoparathyroidism, 3 (4.68%) diabetes mellitus and 6 (9.37%) insulin resistance. We found a significantly higher mean ferritin value in patients with endocrine disturbances of any type compared to subjects without endocrinopathies. In conclusion, our data showed that hypogonadism and short stature were the most frequently found endocrine disturbances. Early form of hypogonadism had a major clinical impact on sexual development and final height. These results suggest that early endocrine evaluation and treatment are necessary in order to improve the quality of life of these patients.
    1. Olivieri NF, Brittenham GM. Iron-Chelating Therapy and the Treatment of Thalassemia. Blood 1997; 89:739-761.
    2. Italian Working Group on Endocrine Complication in Non-endocrine Diseases. Multicenter study on prevalence of endocrine complications in thalassaemia major. Clinical Endocrinology 1995; 42:581-586.
    3. Guidelines for the Clinical Management of Thalassaemia:Thalassaemia International Federation, 2002. (Accessed July 16, 2005, at site <http://www.thalassaemia.org.cy/books/book1/ch1-ch2.doc).
    4. Talmaci R, Traeger-Synodinos J, Kanavakis E, Coriu D, Colita D, Gavrila L. Scanning of &#946;-globin gene for identification of &#946;-thalassemia mutation in Romanian population. J Cell Mol 2004; 2:232-240. [CrossRef]
    5. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM. CDC Growth charts: United States. Advance Data from Vital and Health Statistics of the Centers for Disease Control and Prevention/National Center for Health Statistics 2000; No 314.
    6. Fica S, Barbu C, Vladareanu F, Rotaru R, Albu A. The effects of chronic transfusional regimens on sexual development among homozygous beta thalassemic parients. Abstracts of the 12th International Congress of Endocrinology. Lisbon 2004.
    7. Shalitin S et al. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients. Eur J Haematol 2005;74:93-100. [CrossRef]
    8. Shamshirsaz AA et al. Metabolic and endocrinologic complications in beta-thalassemia major: a multicenter study in Tehran. BMC Endocrine Disorders 2003; 3:4. [CrossRef]
    9. Prototonotariou A, Katopodi A, Zervas A, Livadas S, Konstantellou E, Tolis G. Homozygous &#946;-thalassemia and the gonad. Abstracts of the 3rd International Conference on Recent Developments on the Diagnosis and Therapy of Endocrine and Metabolic Proble
    10. Bergeron C, Kovacs K. Pituitary siderosis: A histologic, immunocytologic, and ultrastructural study. Am J Pathol 1978; 9:295-309.
    11. Bronspeigel-Weintrob N, Olivieri NF, Tyler BJ, Andrews D, Freedman MH, Holland FJ. Effect of age at the start of iron chelation therapy on gonadal function in &#946;-thalassemia major. N Engl J Med 1990; 323:713-719. [CrossRef]
    12. Sklar CA, Lew LQ, Yoon DJ, David R. Adrenal function in thalassemia major following long term treatment with multiple transfusions and chelation therapy. Evidence for dissociation of cortisol and adrenal androgen secretion. Am J Dis Child 1990; 141:327-
    13. Maurer HS, Lloyd-Still JD, Ingrisano C, Gonzalez-Crussi F, Honig CR. A prospective evaluation of iron chelation therapy in children with severe beta-thalassaemia: A six-year study. Am J Dis Child 1988; 142:287-292.
    14. Borgna-Pignatti et al. Growth and sexual maturation in thalassemia major. J Pediatr 1985;106:150-155. [CrossRef]
    15. Chatterjee R, Katz M, Cox TF, Porter JB. Prospective study of the hypothalamic-pituitary axis in thalassaemic patients who developed secondary amenorrhea. Clin Endocrinol 1993; 39:287-290. [CrossRef]
    16. De Sanctis V, Wonke B. Growth and endocrine complications in thalassaemia. Roma: Mediprint 1998;17-19
    17. Piga A, Luzzatto L, Capalbo P, Gambotto S, Tricta F, Gabutti V. High-dose deferoxamine as a cause of growth failure in thalassaemic patients. Eur J Haematol 1988; 40:380-381. [CrossRef]
    18. DeVirgilis S et al. Deferoxamine-induced growth retardation in patients with thalassemia major. J Pediatr 1988; 113:661-669. [CrossRef]
    19. Olivieri NF et al. Growth failure and bony changes induced by deferoxamine. Am J Ped Hematol Oncol 1992; 14:48-56. [CrossRef]
    20. Arcasoy A et al. Effects of zinc supplementation on linear growth in beta thalassemia (a new approach). Am J Hematol 1987; 24:127-136. [CrossRef]
    21. Leek JC, Vogler JB, Gershwin ME, Golub MS, Hurley LS, Hendrickx AG. Studies of marginal zinc deprivation in rhesus monkeys. Fetal and infant skeletal effects. Am J Clin Nutr 1984; 40:1203-1212.
    22. Nishi Y, Hatano S, Aihara K, Fujie A, Kihara M. Transient partial growth hormone deficiency due to zinc deficiency. J Am Coll Nutr 1989; 8:93-97.
    23. Bozzola M et al. Effect of human chorionic gonadotropin on growth velocity and biological growth parameters in adolescents with thalassaemia major. Eur J Pediatr 1989;148:300-303. [CrossRef]
    24. Soliman A. Growth hormone (GH) response to provocation, circulating insuline-like growth factor-1 (IGF-1) and IGF-binding protein-3 concentrations, IGF-1 generation tests and clinical response to GH therapy in children with beta-thalassemia. Abstracts o
    25. Caruso-Nicoletti M et al. Management of puberty for optimal auxological results in betathalassaemia major. J Pediatr Endocrinol Metab 2001;14:939-944.
    26. Aleem A, Al-Momen A, Al-Harakati MS, Hassan A, Al-Fawaz I. Hypocalcemia due to hypoparathyroidism in &#946;-thalassemia major patients. Ann Saudi Med. 2000; 20:364-366.
    27. De Sanctis V, Zurlo MG, Senesi E, Boffa C, Cavallo L, Di Gregorio F. Insulin dependent diabetes in thalassaemia. Arch Dis Child 1988; 63:58-62. [CrossRef]
    28. Dmochowski K, Finegood DT, Francombe WH, Tyler B, Zinman B. Factors determining glucose tolerance in patients with thalassemia major. J Clin Endocrinol Metab 1993; 77:478-483. [CrossRef]
    29. Cavallo-Perin P, Pacini B, Cerutti F, Bessone A, Condo C, Sacchetti L, Piga A, Pagano G. Insulin resistance and hyperinsulinemia in homozygous beta-thalassemia. Metabolism 1995; 44:281-286.
    30. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, Allen CJ, Farrell DE, Harris JW. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994; 331:567-573. [CrossRef]
    31. Olivieri NF et al. Survival of medically treated patients with homozygous thalassemia. N Engl J Med 1994; 331:574-578. [CrossRef]
  • Endocrine Care

    Gunen Yilmaz S, Bayrak S

    Determination of Mandibular Bone Changes in Patients with Primary Hypothyroidism Treated with Levothyroxine Sodium

    Acta Endo (Buc) 2023 19(2): 201-207 doi: 10.4183/aeb.2023.201

    Abstract
    Background. This study aimed to assess fractal dimension (FD) and the radiomorphometric indexes on the digital panoramic radiography (DPR) of patient with primary hypothyroidism receiving levothyroxine sodium replacement therapy. Methods. A total of 115 subjects were included in this cross sectional retrospective study. According to the results of the thyroid function tests, the subjects were divided into two groups as primary hypothyroidism (levothyroxine sodium replacement therapy given), (n = 57) and the healthy control group (n = 58). The fractal dimension (FD), panoramic mandibular index (PMI), mandibular cortical width (MCW), gonial index (GI) and mandibular cortical index (MCI) values of all patients were calculated on DPRs. The statistical analysis of all data was performed with SPSS version 22. Results. The distributions of age and gender in the primary hypothroidism group were similar to control group (p = 0.19 and p = 0.62, respectively). The two groups did not differ statistically significantly in terms of FD, PMI, MCW, GI, and MCI. Conclusion. We determined that mandibular cortical and trabecular bone structure did not significantly differ between healthy individuals and patients receiving drug replacement theraphy due to hypothyroidism, but our results should be further supported with the investigation of clinical parameters.
  • Editorial

    Mihali CV, Petrescu MC, Mandrutiu I, Bechet D, Nistor TV, Turcu V, Ardelean A, Benga G

    Comparison of Plasma Phenylalanine Determination by Densitometry of Thin-Layer Chromatograms and by High Performance Liquid Chromatography in Relation with the Screening of Phenylketonuria

    Acta Endo (Buc) 2017 13(2): 203-208 doi: 10.4183/aeb.2017.203

    Abstract
    Objective. To compare two chromatographic methodologies for determination of plasma phenylalanine (Phe) and their usefulness for diagnosing hyperphenylalaninemia (HPA) and phenylketonuria (PKU). Methods. The plasma amino acids were isolated and concentrated from blood collected from infants with HPA detected by newborn screening. The plasma Phe was determined in parallel by HPLC and by image-densitometry of 2D-TLC plates. Results. Typical examples of 2D-TLC plates and HPLC chromatograms from infants with HPA and PKU are presented and evaluated. The Phe spot was visible on 2D - TLC plates at Phe concentrations higher than 300 μmol/L. The standard calibration curve traced after imagedensitometry of the Phe spot presented high dispersion of values at each concentration of Phe, high SD values, the equation of the curve having a low R-squared value (0.862). In contrast, the standard calibration curve obtained by HPLC shows linearity on the range of concentrations from 100 - 16,000 μmol/L, extremely small SD values, the equation of the curve has a very high R-squared value (0.999). Conclusions. The HPLC methodology is appropriate to confirm HPA detected by newborn or selective screening of PKU. The 2D - TLC methodology is adequate to detect patients with severe PKU.
  • Endocrine Care

    Nanu M, Ardeleanu IS, Brezan F, Nanu I, Apostol A, Moldovanu F, Lazarescu H, Gheorghiu ML, Kozma A

    Neonatal Screening for Congenital Hypothyroidism in Romania: Data From Medilog Medical Information Registry

    Acta Endo (Buc) 2019 15(2): 209-214 doi: 10.4183/aeb.2019.209

    Abstract
    Objective. Congenital hypothyroidism (CH) is one of the common preventable causes of intellectual disability in neonates, by early detection through neonatal screening. We present the 8-year experience of the National Institute for Mother and Child Health (INSMC) in using MEDILOG national registry for the neonatal screening of CH. Methods. Neonatal screening for CH, done by TSH measurement in dried blood spot, is organized in 5 regional centers, each with a reference laboratory. Results. In 2018 80% of all the newborns, from 80% of the maternity hospitals, were registered in MEDILOG. After re-testing of TSH and T4/FT4 from venous blood in positive cases, the incidence of confirmed CH in 2018 was 1/3576 - 1/ 4746. In INSMC center (which includes 26 counties and Bucharest, out of 41 counties), in 2018 the incidence of positive CH cases at screening was 1/2094 (TSH cut-off ≥17 mIU/L) and of confirmed CH cases 1/3576 newborns. For positive screening cases, the median duration from birth to the INSMC laboratory result was 19 days: median of 9 days between screening and laboratory registration and 6 days between registration and test result. Conclusion. MEDILOG registry is a practical instrument for monitoring the steps of neonatal CH screening, the incidence of CH, the evolution of the diagnosed cases, for evaluation of iodine deficiency (by neonatal TSH), and also for research, with the aim of improving early disease detection and treatment.
  • Endocrine Care

    Ustun I, Aydin Y, Ary Arduc A, Berker D, Ozuguz U, Yylmaz M, Erden G, Unlu E

    Evaluation of atherosclerotic risk factors and carotid intima media thickness in healthy offspring of type 2 diabetic patients

    Acta Endo (Buc) 2010 6(2): 211-227 doi: 10.4183/aeb.2010.211

    Abstract
    Aim is to evaluate atherosclerotic risk factors and carotid intima media thickness [CIMT] in offspring of type 2 Diabetes Mellitus [DM] patients with normal glucose tolerance. Methods. We evaluated 96 offspring of Type 2 DM patients and 39 healthy control who were in similar age, sex and body mass. We measured fasting blood glucose [FBG], postprandial blood glucose [PBG], insulin, uric acid, homocystein, fibrinogen, HOMA-IR, lipid profile, hsCRP, microalbuminuria, glycosylated hemoglobin A1c and CIMT by Doppler ultrasonography. Results. FBG was found higher in study group [p<0.001]. The HOMA-IR was 1.7±0.98 and 1.2±0.58 mg/dL x uUI/mL for study and control group, respectively [p=0.007]. TCholesterol, triglycerides, HDL-C, LDL-C and homocystein levels were not different. HsCRP and fibrinogen levels were higher in study group [p=0.014 and p=0.035, respectively]. Microalbuminuria levels were higher in study group but not significant [p=0.111]. CIMT in study group increased distinctively [p<0,001]. In regression analysis, being in study group causes a significant increase on the mean CIMT level by 0.057 mm [0.029-0.086] Conclusion. Our study demonstrated that various atherosclerotic risk factors are aggregated in offspring of Type 2 DM patients having NGT even before they develop glucose intolerance. Having a diabetic family alone might be effective in developing increased CIMT.
  • Editorial

    Catrina SB, Brismar K

    Diabetic foot ulcers. Where we are and where are we going?

    Acta Endo (Buc) 2005 1(2): 213-218 doi: 10.4183/aeb.2005.213

    References
    1. Reiber GE, Lipsky BA, Gibbons GW. The burden of diabetic foot ulcers. Am J Surg 1998; 176(2A Suppl):5S-10S.
    2. Pecoraro RE, Reiber GE, Burgess EM. Pathways to diabetic limb amputation. Basis for prevention. Diabetes Care 1990; 13(5):513-521. [CrossRef]
    3. Veves A, Falanga V, Armstrong DG, Sabolinski ML. Graftskin, a human skin equivalent, is effective in the nagement of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care 2001; 24(2):290-295. [CrossRef]
    4. Gentzkow GD, Iwasaki SD, Hershon KS, Mengel M, Prendergast JJ, Ricotta JJ et al. Use of dermagraft, a cultured human dermis, to treat diabetic foot ulcers. Diabetes Care 1996; 19(4):350-354. [CrossRef]
    5. Bennett SP, Griffiths GD, Schor AM, Leese GP, Schor SL. Growth factors in the treatment of diabetic foot ulcers. Br J Surg 2003; 90(2):133-146. [CrossRef]
    6. Smiell JM, Wieman TJ, Steed DL, Perry BH, Sampson AR, Schwab BH. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomize [CrossRef]
    7. Higley HR, Ksander GA, Gerhardt CO, Falanga V. Extravasation of macromolecules and possible trapping of transforming growth factor-beta in venous ulceration. Br J Dermatol 1995; 132(1):79-85. [CrossRef]
    8. Trengove NJ, Stacey MC, MacAuley S, Bennett N, Gibson J, Burslem F et al. Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors. Wound Repair Regen 1999; 7(6):442-452. [CrossRef]
    9. Catrina SB, Lewitt M, Massambu C, Dricu A, Grunler J, Axelson M et al. Insulin-like growth factor-I receptor activity is essential for Kaposi?s sarcoma growth and survival. Br J Cancer 2005; 92(8):1467- 1474. [CrossRef]
    10. Cao R, Brakenhielm E, Pawliuk R, Wariaro D, Post MJ, Wahlberg E et al. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat Med 2003; 9(5):604-613. [CrossRef]
    11. Hehenberger K, Heilborn JD, Brismar K, Hansson A. Inhibited proliferation of fibroblasts derived from chronic diabetic wounds and normal dermal fibroblasts treated with high glucose is associated with increased formation of l-lactate. Wound Repair Regen [CrossRef]
    12. Loot MA, Kenter SB, Au FL, van Galen WJ, Middelkoop E, Bos JD et al. Fibroblasts derived from chronic diabetic ulcers differ in their response to stimulation with EGF, IGF-I, bFGF and PDGF-AB compared to controls. Eur J Cell Biol 2002; 81(3):153-160. [CrossRef]
    13. Hehenberger K, Hansson A. High glucose-induced growth factor resistance in human fibroblasts can be reversed by antioxidants and protein kinase C-inhibitors. Cell Biochem Funct 1997; 15(3):197-201. [CrossRef]
    14. Cameron NE, Eaton SE, Cotter MA, Tesfaye S. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 2001; 44(11):1973-1988. [CrossRef]
    15. Williamson JR, Chang K, Frangos M, Hasan KS, Ido Y, Kawamura T et al. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 1993; 42(6):801-813. [CrossRef]
    16. Kalani M, Brismar K, Fagrell B, Ostergren J, Jorneskog G. Transcutaneous oxygen tension and toe blood pressure as predictors for outcome of diabetic foot ulcers. Diabetes Care 1999; 22(1):147-151. [CrossRef]
    17. Ballard JL, Eke CC, Bunt TJ, Killeen JD. A prospective evaluation of transcutaneous oxygen measurements in the management of diabetic foot problems. J Vasc Surg 1995; 22(4):485-490. [CrossRef]
    18. Kalani M, Jorneskog G, Naderi N, Lind F, Brismar K. Hyperbaric oxygen (HBO) therapy in treatment of diabetic foot ulcers. Long-term follow-up. J Diabetes Complications 2002; 16(2):153-158. [CrossRef]
    19. Roeckl-Wiedmann I, Bennett M, Kranke P. Systematic review of hyperbaric oxygen in the management of chronic wounds. Br J Surg 2005; 92(1):24-32. [CrossRef]
    20. Norman JT, Clark IM, Garcia PL. Hypoxia promotes fibrogenesis in human renal fibroblasts. Kidney Int 2000; 58(6):2351-2366. [CrossRef]
    21. O?Toole EA, Marinkovich MP, Peavey CL, Amieva MR, Furthmayr H, Mustoe TA et al. Hypoxia increases human keratinocyte motility on connective tissue. J Clin Invest 1997; 100(11):2881-2891. [CrossRef]
    22. Lerman OZ, Galiano RD, Armour M, Levine JP, Gurtner GC. Cellular dysfunction in the diabetic fibroblast: impairment in migration, vascular endothelial growth factor production, and response to hypoxia. Am J Pathol 2003; 162(1):303-312. [CrossRef]
    23. Catrina SB, Okamoto K, Pereira T, Brismar K, Poellinger L. Hyperglycemia regulates hypoxiainducible factor-1alpha protein stability and function. Diabetes 2004; 53(12):3226-3232. [CrossRef]
    24. Elson DA, Thurston G, Huang LE, Ginzinger DG, McDonald DM, Johnson RS et al. Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxiainducible factor-1alpha. Genes Dev 2001; 15(19):2520-2532. [CrossRef]
    25. Breitbart AS, Laser J, Parrett B, Porti D, Grant RT, Grande DA et al. Accelerated diabetic wound healing using cultured dermal fibroblasts retrovirally transduced with the platelet-derived growth factor B gene. Ann Plast Surg 2003; 51(4):409-414. [CrossRef]
    26. Crombleholme TM. Adenoviral-mediated gene transfer in wound healing. Wound Repair Regen 2000; 8(6):460-472. [CrossRef]
    27. Lee PY, Chesnoy S, Huang L. Electroporatic delivery of TGF-beta1 gene works synergistically with electric therapy to enhance diabetic wound healing in db/db mice. J Invest Dermatol 2004; 123(4):791-798. [CrossRef]
    28. Margolis DJ, Crombleholme T, Herlyn M. Clinical protocol: Phase I trial to evaluate the safety of H5.020CMV.PDGF-B for the treatment of a diabetic insensate foot ulcer. Wound Repair Regen 2000; 8(6):480-493. [CrossRef]
    29. Sivan-Loukianova E, Awad OA, Stepanovic V, Bickenbach J, Schatteman GC. CD34+ blood cells accelerate vascularization and healing of diabetic mouse skin wounds. J Vasc Res 2003; 40(4):368-377. [CrossRef]